An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending

Quarterly Review of Economics and Finance

Volumn 49, Issue 4, 2009, Pages 1260-1274

  Vernon, John A ^a,b   Golec, Joseph H ^c   Lutter, Randall ^d   Nardinelli, Clark ^d  

^a IL   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

FDA; Prescription drug user fee act; R D spending

Indexed keywords

EID: 70350599516     PISSN: 10629769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.qref.2009.08.005     Document Type: Article

References (30)

1. Abbott T.A. Price regulation in the pharmaceutical industry: Prescription or placebo. Journal of Health Economics 14 (2005) 551-565
2. Berndt E.R., Gottschalk A.H., Philipson T., and Strobeck M.W. Assessing the impacts of Prescription Drug User Fee Acts (PDUFA) on the FDA approval process (2004), AEI-Brookings Joint Center for Regulatory Studies
3. Berndt, E. R, Glennerster, R. G, & Kremer, M. R., et al. (2006). Advanced purchase commitments for a malaria vaccine: Estimating costs and effectiveness. National Bureau of Economic Research, Working paper 11288, Cambridge, MA.
4. Branch B. Research and development activity and profitability: A distributed lag analysis. Journal of Political Economy 82 5 (1974) 999-1011
5. Carpenter D. The political economy of FDA drug approval: Processing, politics and implications for policy. Health Affairs 23 1 (January/February 2004) 52-63
6. DiMasi J.A. New drug development in the United States from 1963 to 1999. Clinical Pharmacology & Therapeutics 69 (2001) 286-296
7. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
8. Ellison S.F., and Mullin W.P. Gradual incorporation of information: Pharmaceutical stocks and the evolution of president Clinton's health care reform. Journal of Law and Economics 44 (2001) 89-130
9. Ellison, S. F., & Wolfram, C. D. (2001). Pharmaceutical prices and political activity. National Bureau of Economic Research, working paper 8482, Cambridge, MA.
10. Fazzari S., Hubbard G., and Petersen B. Financing constraints and corporate investment. Brookings Paper on Economic Activity (1988)
11. Giaccotto C., Santerre R.S., and Vernon J.A. Drug prices and R&D investment behavior in the pharmaceutical industry. Journal of Law and Economics 48 1 (2005) 195-214
12. Golec, J. H, & Vernon, J. A. (2006). European pharmaceutical price regulation, firm profitability, and R&D spending. University of Connecticut, Department of Finance, Working Paper.
13. Golec, J. H, Hegde, S., & Vernon, J. A. (2005). Pharmaceutical stock price reactions to price constraint threats and firm-level R&D spending. National Bureau of Economic Research, working paper 11229, Cambridge, MA.
14. Grabowski H.G. The determinants of industrial research and development: A study of the chemical, drug, and petroleum industries. Journal of Political Economy 76 (1968)
15. Grabowski H.G. Health reform and pharmaceutical innovation (1994), Washington, DC, AEI Press
16. Grabowski H.G., and Vernon J.M. The determinants of R&D expenditures in the pharmaceutical industry. In: Robert Helms (Ed). Drugs and health (1981), AEI Press, Washington, DC
17. Grabowski H.G., and Vernon J.M. A new look at the risks and returns to pharmaceutical R&D. Management Science 36 7 (1990) 804-821
18. Grabowski H.G., and Vernon J.M. The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics 10 (2000) 201-215
19. Hall, B. H. (1992). Investment and research and development at the firm level: Does the source of financing matter? National Bureau of Economic Research, working paper 4096, Cambridge, MA.
20. Hubbard G. Capital market imperfections and investment. Journal of Economic Literature XXXVI (1998)
21. Lichtenberg, F. (2002). Sources of U.S. longevity increase, 1960-1997. National Bureau of Economic Research, working paper 8755, Cambridge, MA.
22. Philipson T., Berndt E.R., Gottschalk A.H., and Strobeck M.W. Assessing the safety and efficacy of the FDA: The case of the prescription drug user fee acts. Journal of Public Economics 92 6 (2005) 1306-1325
23. Philipson, T., Berndt, E. R., Gottschalk, A. H., & Strobeck, M.W. (2005b). Assessing the safety and efficacy of the FDA: The case of the prescription drug user fee acts. National Bureau of Economic Research, working paper 11724, Cambridge, MA.
24. PhRMA Industry Profile. (2006). Washington, D.C., March 2006.
25. Scherer F.M. Industry structure, strategy, and public policy (1996), Harper Collins
26. Scherer F.M. The link between gross profitability and pharmaceutical R&D spending. Health Affairs 20 (2001) 216-220
27. Schwartz, E. (2003). Patents and R&D a real options. National Bureau of Economic Research, working paper 10114, Cambridge, MA.
28. U.S. Congressional Budget Office. (1998). How increased competition from generic drugs has affected prices and returns from the pharmaceutical industry, July 1998.
29. Vernon J.A. Drug research and price controls. Regulation 25 4 (2003)
30. Vernon J.A. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 14 1 (2005) 1-17